Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Half Year Report 2023

September 27, 2023

OBSV_June 30_Interim financialsDownload

Investor presentations

HCW Presentation September 13, 2021

ObsEva-Corporate-Deck_HCW_Final-Download

Canaccord Presentation August 12, 2021

ObsEva-Corporate-Deck_CanaccordDownload

Wedbush Presentation August 11, 2021

ObsEva_Corporate-Deck-2021-WedbushDownload

HCW Presentation March 9, 2021

ObsEva-HCW-Conference-Slides_March 9, 2021Download

SVB Leerink Presentation Feb 24, 2021

ObsEva Fireside chat_SVB Leerink_Feb 2021Download

JPM Presentation Jan 14, 2021

ObsEva_JPM Deck_1_14_2021Download

Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

P12 W52_76_10 Dec 2020Download

Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020

ObsEva_November2020presentation_jefferies 18.11Download
1 2 3

Press Releases

ObsEva Files half Year 2023 Financial Statements

press release

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 –…

Read more

ObsEva Recovers Full Worldwide Rights on Nolasiban

press release

July 13, 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – July 13, 2023 – ObsEva SA (SIX: OBSN), a…

Read more

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023

press release

June 30, 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 30, 2023 –…

Read more
1 2 3 … 85

General Meetings

ObsEva Extraordinary General Meeting 2018

January 28, 2018

Read more

ObsEva Annual General Meeting 2017

June 13, 2017

Read more
1 2 3 4

Upcoming Events

Half Year 2023 Financial Results: 27 September 2023

Event


    Read more
     

    Stock Information

    Latest Press Release

    ObsEva Files half Year 2023 Financial Statements

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 –…

    Read more

    Investor Contact


    IR@obseva.ch

    Media Contact

    Media

    contact@obseva.ch

    Contacts

    ObsEva Switzerland Office

    Chemin des Aulx,12

    1228, Plan-Les-Ouates, Geneva, Switzerland

    +41 (0)22 552 3840


    contact@obseva.ch

    Media

    contact@obseva.ch

    Investor relations


    IR@obseva.ch

    CEO Office

    +41 (0)22 552 1550


    contact@obseva.ch

     

    Sign up for news

     
     

      * Type:


      InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












      Read our privacy policy here.


       

      Are you sure you want to leave ObsEva.com?

      We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

      Continue to link

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue